Arca
Skip to content
Tools
Tools

Acquired immunodeficiency syndrome

Drug research and approvals for acquired immunodeficiency syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 598 studies of acquired immunodeficiency syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 1 approved and 9 open orphan designations naming it.

  • Recruiting worldwide: 598
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting now

Newest posted first, of 598 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 3

Phase 3 12 of 30

  • Tenofovir disoproxilHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
  • LamivudineHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
  • RitonavirHuman immunodeficiency virus type 1 protease inhibitor
  • EfavirenzHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
  • CobicistatCytochrome P450 3A inhibitor
  • LopinavirHuman immunodeficiency virus type 1 protease inhibitor
  • ZidovudineHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
  • DarunavirHuman immunodeficiency virus type 1 protease inhibitor
  • Tenofovir alafenamideHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
  • ElvitegravirHuman immunodeficiency virus type 1 integrase inhibitor
  • NevirapineHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
  • TenofovirHuman immunodeficiency virus type 1 reverse transcriptase inhibitor

Phase 2 12 of 25

Phase 1 or earlier 10

How its trials ended

1,760 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 402 whose ending is known, 58% met their primary endpoint, 11% missed it and 31% stopped early.

  • Completed, result not reported1,03459%
  • Met its primary endpoint23313%
  • Ongoing19511%
  • Status unknown1297%
  • Stopped: other or unclear784%
  • Missed its primary endpoint432%
  • Stopped: enrollment or feasibility181%
  • Stopped: lack of efficacy101%
  • Stopped: sponsor or business decision101%
  • Stopped: funding8<1%
  • Stopped: safety2<1%

FDA orphan designations

Approved first, then open designations, newest first
Mar 4, 1996Vitrasert ImplantTreatment of CMV retinitis in patients with acquired immunodeficiency syndrome.Bausch & Lomb Surgical, Chiron Vision ProductsApproved
Jul 17, 2002RubitecanTreatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndromeSuperGen, Inc.Designated
Mar 24, 1992HIV neutralizing antibodiesTreatment of acquired immunodeficiency syndrome.Hemacare CorporationDesignated
Nov 21, 1989CD4 human truncated 369 AA polypeptideTreatment of acquired immunodeficiency syndrome.SmithKline BeechamDesignated
Nov 20, 19893'-azido-2',3'dideoxyuridineTreatment of acquired immunodeficiency syndrome.Berlex Laboratories, Inc.Designated
Nov 20, 1989Recombinant soluble human CD4Treatment of acquired immunodeficiency syndrome.Biogen, Inc.Designated
Nov 15, 1988Interferon beta, recombinant humanTreatment of acquired immunodeficiency syndrome.Berlex Laboratories, Inc.Designated
Jun 22, 1988DideoxyinosineTreatment of acquired immunodeficiency syndrome.Bristol-Myers SquibbDesignated
Nov 9, 1987Ammonium trichloro [dioxoethylene-O,O') tellurium (IV)Treatment of acquired immunodeficiency syndrome.NPDC-AS101, Inc.Designated
Jul 17, 1985Ammonium 21-tungsto-9-antimoniateTreatment of acquired immunodeficiency syndrome.Rhone-Poulenc Rorer Pharm.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.